Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TK2 | O00142 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583331 | 1.00 | TK1 (0.44) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL15893327 | 1.00 | TK1 (0.44) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL6025793 | 0.88 | TK1 (0.43) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL18039264 | 0.88 | TK1 (0.43) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL6025787 | 0.88 | TK1 (0.43) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL4745548 | 0.86 | TK1 (0.43) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL292198 | 0.86 | LMNA (0.45) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL12482651 | 0.86 | TK1 (0.45) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL6014063 | 0.86 | TK1 (0.40) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL5888914 | 0.85 | TK1 (0.40) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160082133-A1 | CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MRI USING REPORTER GENES AND SUBSTRATES AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | claimed |
| WO-2014172359-A1 | CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MRI USING REPORTER GENES AND SUBSTRATES AND METHODS THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-23 | — | — | WO | claimed |
| US-11253611-B2 | Thymidine kinase diagnostic assay for gene therapy applications | Genvivo, Inc. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20190328904-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | Genvivo, Inc. | 2019-10-31 | — | — | US | disclosed |
| US-10350302-B2 | Thymidine kinase diagnostic assay for gene therapy applications | Genvivo, Inc. (US) | 2019-07-16 | — | — | US | disclosed |
| EP-2967078-B1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | GENVIVO INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180264137-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | Genvivo, Inc. | 2018-09-20 | — | — | US | disclosed |
| US-9999683-B2 | Method for identifying and treating a patient having tumor lesions comprising administering a gene therapy retroviral vector particle comprising a mutated HSV-thymidine kinase (HSV-TK) polynucleotide | EPEIUS BIOTECHNOLOGIES CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20160082133-A1 | CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MRI USING REPORTER GENES AND SUBSTRATES AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| EP-2967078-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | Epeius Biotechnologies Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014172359-A1 | CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MRI USING REPORTER GENES AND SUBSTRATES AND METHODS THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140294772-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | EPEIUS BIOTECHNOLOGIES CORPORATION (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014153205-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | EPEIUS BIOTECHNOLOGIES CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |